Poolbeg Pharma Identifies New RSV Drug Candidates
Date
12/22/2022 2:03:59 PM
(MENAFN- News Direct) London, UK | December 22, 2022 05:47 AM Eastern Standard Time
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing that Poolbeg has identified several potential candidates from its Respiratory Syncytial Virus (RSV) AI collaboration with One Three Biotech. He also looks back on what the company achieved during 2022 and looks ahead to what investors can expect from Poolbeg in 2023.
MENAFN22122022005728012573ID1105343851
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.